

# Antipsychotic (6 to < 18 Years of Age)

Maximum Length of Approval = 180 Days

Note: Form must be completed in full.

Recipient's Medicaid ID# Date of Birth (MM/DD/YYYY)																						
							1	\		1												
220							•			•					]							
Reci	pient's Full Name																					
Pres	criber's Full Name																					
Duas	aribaria NDI																					
Pres	criber's NPI																					
Pres	criber's Phone Number		1 1	1	1						Pres	crib	er's	Fax l	Num	ber						
	-	-												-				-				
				-	1							l		<u>.</u>								
PRO	PROVIDER TYPE OR SPECIALTY: CHILD UNDER STATE CARE/CUSTODY: Yes No												No									
PATI	ENT: Male	☐ Fema	ale					ı	MEDI	CATI	ON R	EQUI	EST:		<u> </u>	New			Cont	inua	tion	
HEIG	HEIGHT: in / □ cm WEIGHT: □ lbs / □ kgs BMI: *BMI %:																					
BMI Calculator: * https://www.cdc.gov/healthyweight/bmi/calculator.html												<u>ntml</u>										
1.	1. Medication Requested:																					
	Requested Antipsych	Strength					Directions								Quantity							
2.	Diagnosis:																					
			Disrupt	ive Be	havi	or Di	isor	der			Disr	uptiv	e M	ood	Dvsi	reaul	ation	Dis	orde	er		
	☐ Autism Spectrum		Schizor									•			•	-						
	 ☐ Bipolar Disorder		Schizoa			isord	der															
	·																					•
3.	Target Symptoms:	☐ Aggre	ssion	☐ Ir	npuls	sivity	'	□ I	rrital	oility		□ s	elf I	njuri	ous	Beha	vior					
	(check all that apply)								Othe	r: _												
						_	<b>-</b> -															
4.	Severity of Target Syr	•	:		Mild	L		Mod				3 Ma					evere				reme	
5.	Functional Impairmen	nt:		∐ 1	Mild	L	2	Mod	lerat	е	□;	3 Ma	rkec	l		4 S	evere	9	∐ 5	Ext	reme	!
6.	Previous Antipsychot	ic Trials	in last	12 Mc	onths	s																
	Antipsychotic Me		S	tart [	Date	ates			End Dates				Maximum			n Dose (Per Day)						
																			•		• .	
																			•			



### **Antipsychotic (6 to < 18 Years of Age)**

Maximum Length of Approval = 180 Days

Note: Form must be completed in full.

Rec	ipient's	Full Nam	ne																			
7.		other pressan									s taki	ng c	oncu	ırrent	ly witl	n the	anti	psych	otic (i	.e.,		<u> </u>
	Psycho					13, 6		e/day		1	Psyc	hoth	erap	eutic	Medic	atio	n		Dose	e/day	,	
8.	Ration	ale for p	orescri	bing	antips	ycho	otic ab	ove r	naxi	mum r	ecom	men	ded	dose	? (if a	pplic	able	)				
9.	ls you	intent	to targ	et lov	ver do	se a	ntipsy	choti	c tre	atmen	t?											
	□,	Yes	☐ No																			
10.	Ration	ale for p	orescri	bing	2 or m	ore	antips	ycho	tics	for >60	) day	s (if a	appli	cable	):							
							_															
11.	If your																					
	-	olan to		aper,		-	-			-							-					
		Yes	☐ No		li	f YES	S, pleas	se pro	vide	the cro	ss tap	er pl	an: _									
12.	Have n	netaboli	ic mon	itorin	g labs	* (fa	sting l	ipids	and	gluco	se) b	een p	perfo	rmed	withi	n the	last	6 moi	nths?			
		l lab res		ost red	-						ation	of the	erapy	, labs	are re	quire	d.					
	□,	Yes	□No		Date:																	
13.	Has an	assess	ment	for Ta	rdive	Dys	kinesia	a (TD)	) be	en don	e in t	he la	st 6	mont	hs?							
	AIMs: *Officia	☐ Ye I Form or		☐ No n (mos		nt) mu		CUS:	_	] Yes	ĺ	□ No	)	I	Date: <sub>-</sub>							
14.	Monito	ring Pla	an: R	TC: _					I	Labs: c	l	m	onth	ıs .	TD Sc	reen:	q _		_ mon	ths		
	Labs:	□ C	вс	☐ Pr	olactin		_ СМБ	- <u></u>	] Lipi	id Profi	le	□ o	ther,	speci	fy:							
15.	Next A	ppointr	nent D	ate: _						_												
Pre	scriber's	Signatu	ıre:												D	ate:						_
REC	QUIRED	FOR RE	/IEW: A	II cop	ies of ı	medi	cal rec	ords (	e.g.,	diagno	stic e	valua	tions	and i	ecent							
сор	ies of re	lated lab	s. The	provid	ler mus	st ret	ain cop	oies of	fallo	docume	entatio	n for	five	years.	i							

Fax this form to 1-866-940-7328

Pharmacy PA Call Center: 1-800-310-6826

Confidentiality Notice: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender (via return fax) immediately and arrange for the return or destruction of these documents. Distribution, reproduction or any other use of this transmission by any party other than the intended recipient is strictly prohibited.



# **Antipsychotic (6 to < 18 Years of Age)**

Maximum Length of Approval = 180 Days

Note: Form must be completed in full.

FDA-approved agents and doses are considered most appropriate.

		FDA Information for 6–17 Age Group
Medication and Approved Use	Age Range	Dosing Instructions
		Aripiprazole
Bipolar Disorder	Pediatric age	Initial dose: 2 mg/day
(manic or mixed	10–17	Recommended dose: 10 mg/day
episodes)		Maximum dose: 30 mg/day
Schizophrenia	Pediatric age	Initial dose: 2 mg/day
	13–17	Recommended dose: 10 mg/day
		Maximum dose: 30 mg/day
Irritability associated	Pediatric age	Initial dose: 2 mg/day
with Autism	6–17	Recommended dose: 5-10 mg/day
		Maximum dose: 15 mg/day
		Lurasidone
Bipolar I Disorder	Pediatric age	Initial dose: 20 mg/day
(depression)	10-17	Recommended dose: 20-80 mg/day
		Maximum dose: 80 mg/day
Schizophrenia	Pediatric age	Initial dose: 40 mg/day
-	10-17	Recommended dose: 40-80 mg/day
		Maximum dose: 80 mg/day
1		Olanzapine
Bipolar I Disorder	Pediatric age	Oral Formulation
(manic or mixed	13–17	Initial dose: 2.5–5 mg/day
epidsodes)		Target dose: 10 mg/day
Schizophrenia	Pediatric age	Initial dose: 2.5–5 mg/day
	13–17	Target dose: 10 mg/day
·		Paliperidone
Schizophrenia	Pediatric age	Weight < 51kg: Initial Dose (3 mg/day)
	12–17	Recommended Dose (3–6 mg/day)
		Maximum Dose (6 mg/day)
		Weight ≥ 51kg: Initial Dose (3 mg/day)
		Recommended Dose (3–12 mg/day)
		Maximum Dose (12 mg/day) Risperidone
Ringlar I Disorder	Pediatric age	
Bipolar I Disorder (manic or mixed	Pediatric age 10–17	Initial dose: 0.5 mg/day Titration: 0.5–1 mg/day
episodes)	10-17	Recommended dose: 2.5 mg/day
opioodos)		Effective dose range: 0.5–6 mg/day
		Lifective dose range. 0.5-0 mg/day

Confidentiality Notice: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender (via return fax) immediately and arrange for the return or destruction of these documents. Distribution, reproduction or any other use of this transmission by any party other than the intended recipient is strictly prohibited.



# **Antipsychotic (6 to < 18 Years of Age)**

Maximum Length of Approval = 180 Days

Note: Form must be completed in full.

	FDA Information for 6–17 Age Group									
Medication and Approved Use	Age Range	Dosing Instructions								
Irritability associated	Pediatric age	<b>Initial dose:</b> 0.25 mg/day (< 20 kg); 0.5 mg/day (≥ 20 kg)								
with Autism	5–16	<b>Titration:</b> 0.25–0.5 mg at > or = 2 weeks								
		Recommended dose: 0.5 mg/day (< 20 kg; 1 mg/day (≥ 20 kg)								
		Effective dose range: 0.5–3 mg/day								
Schizophrenia	Pediatric age	Initial dose: 0.5 mg/day								
	13–17	Titration: 0.5–1 mg/day								
		Target dose: 3 mg/day								
		Effective dose range: 1–6 mg/day								
		Quetiapine								
Bipolar I Disorder	Pediatric age	Information provided is for the immediate release table formulation								
(mania)	10–17	Day 1: 25 mg twice a day								
		Day 2: Twice daily dosing totaling 100 mg								
		Day 3: Twice daily dosing totaling 200 mg								
		Day 4: Twice daily dosing totaling 300 mg								
		Day 5: Twice daily dosing totaling 400 mg								
		Further adjustments should be in increments no greater than 100 mg/per day								
		within the recommended dose range of 400–600 mg/per day. Based on response and tolerability, may be administered three times daily.								
Schizophrenia	Pediatric age	Information provided is for the immediate release tablet formulation								
	12–17	Day 1: 25 mg twice daily								
		Day 2: Twice daily dosing totaling 100 mg								
		Day 3: Twice daily dosing totaling 200 mg								
		Day 4: Twice daily dosing totaling 300 mg								
		Day 5: Twice daily dosing totaling 400 mg								
		Recommend dose range: 400–800 mg/day								
		Further adjustments should be in increments no greater than 100 mg/per day								
		within the recommended dose range of 400–800 mg/per day. Based on response								
		and tolerability, may be administered three times daily.								

### **Helpful Links:**

- Access the following information at <a href="http://floridabhcenter.org/index.html">http://floridabhcenter.org/index.html</a>:
  - Antispychotic High Dosing Table for Children and Adolescents
  - AIMS/DISCUS forms
  - Florida Medicaid Best Practice Psychotherapeutic Medication Guidelines for Children and Adolescents
- The Centers for Disease Control and Prevention (CDC) BMI Calculator for Children and Teens: <a href="https://www.cdc.gov/healthyweight/bmi/calculator.html">https://www.cdc.gov/healthyweight/bmi/calculator.html</a>

**Confidentiality Notice:** The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender (via return fax) immediately and arrange for the return or destruction of these documents. Distribution, reproduction or any other use of this transmission by any party other than the intended recipient is strictly prohibited.